Why didn’t achieving an LDL-C of 16mg/dl 6 weeks after MI and an LDL-C difference between groups of 40mg/dl at week 6 with the aforementioned rationale translate into significant clinical benefits at 1 year?
What happened
First-line evolocumab before PCI for acute MI improved LDL-C target achievement at 1 year but did not reduce all-cause death or cardiovascular hospitalization.
Why didn’t achieving an LDL-C of 16mg/dl 6 weeks after MI and an LDL-C difference between groups of 40mg/dl at week 6 with the aforementioned rationale translate into significant clinical benefits at 1 year?
“The lack of a clear effect on cardiovascular outcomes in the primary analysis suggests evolocumab may not have early clinically meaningful pleiotropic effects and the benefit of lipid lowering may require more time. Immediate in-hospital initiation of evolocumab substantially improved LDL-C goal attainment but even then, 1 in 5 patients failed to reach their target a year later. Developing additional preventive strategies and delivering them early remains an imperative for high-risk patients.”
Dr. Gilles Montalescot
AMUNDSEN does not show PCSK9i fail after MI, only no detectable 1-year event benefit.
X post ↗Too little ezetimibe in the comparator, and full statin plus ezetimibe from day one might do better.
X post ↗Earlier LDLc lowering is better, and the neutral event result fits larger PCSK9i outcome trials.
X post ↗Much better LDL target attainment, but no 1-year clinical event reduction.
X post ↗Evolocumab before PCI made guideline LDL goals achievable, but LDL lowering is a marathon, not a sprint.
X post ↗Calls it an open debate: 89% on evolocumab reached LDLc <55mg/dl but clinical outcomes did not differ from high intensity LLT.
X post ↗Endorses the accompanying editorial's message that LDL lowering is a marathon not a sprint.
X post ↗“#AMUNDSEN at #ESCCongress #HOTLINE Can starting a PCSK9 inhibitor before PCI improve lipid control and early outcomes after acute MI? 2,161 patients with STEMI/NSTEMI undergoing urgent PCI Evolocumab + standard lipid therapy vs standard care LDL-C goal at 1 year: 82% vs”
X ↗Cath Lab After Hours
“AMUNDSEN trial: start evolocumab before PCI, hit the LDL target — but do not claim fewer events. Immediate evolocumab plus high-intensity lipid-lowering therapy more than doubled target attainment after acute MI. The lipid result was striking. But the 1-year clinical result”
X ↗Mohammed Al-Qadami
“tarting evolocumab before PCI increased LDL-C target attainment to 82% vs 40%, but did not reduce death or unplanned CV hospitalization at 1 year. Strong lipid effect without early clinical benefit.”
X ↗Open questions from this trial that would benefit from expert input.
Answers are grounded in this paper and cite their sources.
Why the trial, tables, limitations, PICO, abstract, media & sources
Statin therapy takes weeks to lower LDL cholesterol, leaving early post-infarction risk unaddressed. AMUNDSEN asked whether giving the PCSK9 inhibitor evolocumab immediately before primary PCI for acute myocardial infarction confers additional early benefit over standard lipid-lowering alone.
Does evolocumab started before PCI improve LDL-C control and clinical outcomes at 1 year in patients with high-risk acute MI?
| Outcome | Evolocumab | Standard care |
|---|---|---|
| LDL-C <55 mg/dL + >=50% reduction at 12 months Adjusted OR 5.54 (95% CI 4.50-6.82); P<.001 | Evolocumab 792/970 (82%) | Standard care 370/934 (40%) |
| Median LDL-C at 6 weeks Rapid separation after in-lab initiation | Evolocumab 16 mg/dL | Standard care 56 mg/dL |
| All-cause death or unplanned CV hospitalization Main clinical endpoint - adjusted OR 0.94 (0.73-1.19); P=.59 - no benefit at 1 year | Evolocumab 159/1087 (14.6%) | Standard care 165/1074 (15.4%) |
Does evolocumab started before PCI improve LDL-C control and clinical outcomes at 1 year in patients with high-risk acute MI?
Experts agree that starting evolocumab in the cath lab during a heart attack sharply improved cholesterol goal attainment but did not reduce clinical events at one year, so they read it as a lipid win rather than proof of early outcome benefit.
Commentators accept the striking cholesterol result and the flat one-year clinical result at face value. Most frame the trial as showing that the usual stepwise approach leaves many heart attack patients short of target, and caution against reading it as evidence that the drug class fails after a heart attack. The live question is whether longer follow-up will show event benefit, and whether a stronger upfront statin plus ezetimibe strategy could achieve much of the same.
Several clinicians independently state the same two-part reading: early evolocumab produced far better LDL-C target attainment, but no reduction in death or cardiovascular hospitalization at one year. Some add that a longer horizon is needed to judge clinical benefit.
Upfront PCSK9 inhibitor pathway vs fuller statin plus ezetimibe from day one.
What they’re arguing about
supportiveneutralcautiouscritical
Counts are expert takes we classified by axis. Tap a row to see the takes behind its count.
Experts say longer follow-up is needed to see whether the deep early LDL-C lowering translates into fewer clinical events. It is also open whether full statin plus ezetimibe therapy from day one would narrow the gap with evolocumab.
First-line evolocumab administered before PCI in acute MI significantly improved LDL-C target achievement at 1 year but did not reduce all-cause death or unplanned cardiovascular hospitalization, arguing against acute pleiotropic clinical benefits.
Importance: Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibition is recommended as second- or third-line lipid-lowering therapy after myocardial infarction (MI), resulting in prolonged periods of inadequate low-density lipoprotein cholesterol (LDL-C) control. Whether in-catheterization laboratory decision of PCSK9 inhibition, started before mechanical reperfusion, could improve LDL-C control and clinical outcomes at 1 year is unknown. Objective: To evaluate evolocumab as first-line therapy vs standard care in patients with high-risk acute MI undergoing percutaneous coronary intervention (PCI). Design, Setting, and Participants: This international, phase 4, prospective randomized, open, blinded end-point adjudication study was conducted at 48 sites in 6 countries. Adults with high-risk ST-elevation MI (STEMI; aged >55 years) or non-ST-elevation MI (NSTEMI) with 1 or more additional high-risk characteristics were enrolled beginning September 29, 2021, through May 22, 2025, with final follow-up on May 22, 2026. Interventions: Patients were randomized 1:1 to receive evolocumab 140 mg subcutaneously every 2 weeks for 1 year (first injection before PCI) in addition to standard care (n = 1087) or standard care alone (n = 1074). Standard care included high-intensity oral lipid-lowering therapy with the optional PCSK9 inhibitor use per guideline indication in the control group. Main Outcomes and Measures: The primary outcome was LDL-C less than 55 mg/dL and at least 50% reduction in LDL-C from baseline at 12 months. The main clinical end point was all-cause death or unplanned cardiovascular hospitalization at 12 months. Results: Among 2161 randomized patients (mean age, 67 years; 1703 males [79%]; 1261 [58%] with STEMI; 900 [42%] with NSTEMI), the primary outcome was achieved in 792 of 970 patients (82%) with evolocumab vs 370 of 934 (40%) with standard care (adjusted odds ratio, 5.54 [95% CI, 4.50-6.82]; P < .001). At 6 weeks, median LDL-C was 16 mg/dL with evolocumab vs 56 mg/dL with standard care. The main clinical end point occurred in 159 of 1087 patients (14.6%) with evolocumab vs 165 of 1074 (15.4%) with standard care (adjusted odds ratio, 0.94 [95% CI, 0.73-1.19]; P = .59). Conclusions and Relevance: In patients with acute MI undergoing PCI, first-line evolocumab combined with high-intensity lipid-lowering therapy produced rapid and sustained LDL-C reduction, with more than 80% of patients reaching the guideline-recommended target at 1 year. However, no clinical benefit was detected during the first year of follow-up, arguing against clinically meaningful acute pleiotropic effects of PCSK9 inhibitors in addition to standard care. Trial Registration: ClinicalTrials.gov Identifier: NCT04951856.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Montalescot et al. (2026) conducted an RCT in Acute myocardial infarction (n=2,161). Evolocumab vs. Standard care was evaluated on LDL-C less than 55 mg/dL and at least 50% reduction in LDL-C from baseline at 12 months (OR 5.54, 95% CI 4.50-6.82, p=<.001). First-line evolocumab before PCI for acute MI improved LDL-C target achievement at 1 year but did not reduce all-cause death or cardiovascular hospitalization.
Synapse has enriched 10 related papers. Consider them for comparative context: